On this episode of Advances in Care, host Erin Welsh hears from Dr. Meghna Trivedi, an oncologist at NewYork-Presbyterian and Columbia, who is spearheading new research to assess cancer patients’ risk of developing chemotherapy induced peripheral neuropathy–an all too common side effect of cancer treatment.

Dr. Trivedi describes a study that she and her team undertook to identify and assess patient risk for developing a specific type of chemotherapy-induced neuropathy called TIPN, which is caused by taxanes, a commonly used chemotherapy drug. Based on this SWOG trial, known as S1714, physicians are better able to monitor at-risk patients for these side effects and adjust their treatment regimens accordingly.

Then, Dr. Trivedi explains how her team–also led by Dr. Daniel Hertz, PharmD, PhD at the University of Michigan–was recently awarded a prestigious R37 grant to identify a biomarker for TIPN.  This study, which she co-leads with Dr. Daniel Hertz, PharmD, PhD at the University of Michigan, will help doctors understand the mechanisms for why TIPN develops in the first place, and will be a critical step forward in creating targeted therapies to treat this disease before it starts.

Finally, Dr. Trivedi dives into the clinical trials her team is currently conducting to identify new therapeutic approaches to address and prevent the effects of neuropathy, such as cryotherapy.

***

Dr. Meghna Trivedi, is a medical oncologist at NewYork-Presbyterian and co-leads the Hereditary Breast and Ovarian Cancer Program at Columbia’s Herbert Irving Comprehensive Cancer Center, a comprehensive, multi-disciplinary initiative aimed at screening, preventing, diagnosing, and treating hereditary breast and ovarian cancer. This innovative program brings together the resources of a world-renowned academic institution, including cutting-edge genomic testing, clinical trials, and experts in hereditary cancers across different specialties. Dr. Trivedi’s research and care expertise also includes cancer genetics and genomics, precision medicine, and chemotherapy induced peripheral neuropathy. She is the principal investigator on several clinical trials, and has authored numerous publications in leading peer-reviewed journals.

To learn more about the SWOG trial visit swog.org/clinical-trials/s1714

For more information visit nyp.org/Advances